Outperformed Approved Pan-HDAC Inhibitor Givinostat in Improving Muscle Function and Correcting Drivers of DMD Cardiomyopathy New Data Confirm TN-301’s Differentiated Mechanism and Opportunities to ...

NMD Pharma will also present an update on the ongoing SYNAPSE-MG Phase 2b clinical trial of ignaseclant in generalized myasthenia gravisAarhus, ...

Deramiocel has the potential to become the first therapy to address both skeletal and cardiac manifestations of Duchenne muscular dystrophyBLA ...

Recent research from the University of Houston College of Pharmacy identifies key mechanisms of skeletal muscle regeneration and growth of muscles following resistance exercise. It's a finding that ...

Muscle loss (atrophy) due to inactivity is common after illness, injury, hospitalization or falls, and becomes increasingly frequent with aging. New research published in Advanced Science shows that ...

Researchers explored the effect of immune checkpoint inhibitors on psoas muscle density and skeletal muscle index in patients with melanoma.

Researchers have identified a protein that’s critical to the development of skeletal muscle mass and strength and the tissue’s ability to metabolize glucose. They say their findings may lead to ...

Skeletal muscle loss is a risk factor for developing dementia, according to a study being presented today at the annual meeting of the Radiological Society of North America (RSNA). Skeletal muscles ...

Vitamin D deficiency, rampant in India at 70–90% of the population, adds another layer of trouble by curbing calcium ...

The MarketWatch News Department was not involved in the creation of this content. -- NMD Pharma will also present an update on the ongoing SYNAPSE-MG Phase 2b clinical trial of ignaseclant in ...